Celcuity Sets the Stage at Esteemed Healthcare Conference
Celcuity Inc. (Nasdaq: CELC), a pioneering name in the biotechnology landscape, is all set to participate in the 8th Annual Evercore Healthcare Conference. This significant event will occur over several days, bringing together industry leaders in Miami, where Celcuity plans to highlight its innovative approaches to oncology therapies.
Leadership Insights from the CEO
Brian Sullivan, the Chief Executive Officer and Co-founder of Celcuity, is slated to take the stage for a fireside chat. Scheduled for the early hours of December 3, this session promises to provide valuable insights into Celcuity's strategic direction and the clinical advances being made in targeted therapy development. This format allows for a rich dialogue, engaging both the audience and the listeners worldwide.
Webcast Availability
For those unable to attend in person, a live webcast will be available, ensuring that the broader community can stay informed about the discussions and insights shared. Participants can access the webcast through a link provided by Celcuity, allowing engagement from anywhere. Furthermore, a replay will be available post-event, which is an excellent opportunity for stakeholders to catch up on the insights shared during the conference.
Celcuity's Innovative Approach to Oncology
At the heart of Celcuity’s mission is the commitment to pioneering targeted therapies for various solid tumors. The lead therapeutic candidate, gedatolisib, has shown promising potential as it acts on key biological pathways crucial in many cancers. This pan-PI3K and mTORC1/2 inhibitor distinguishes itself from other therapies by effectively targeting multiple aspects of the PI3K pathway, thus opening new possibilities for treatment.
A Glimpse into Clinical Trials
Celcuity continues to push the boundaries with ongoing clinical trials. The Phase 3 clinical trial VIKTORIA-1 has reached key milestones, evaluating gedatolisib's effectiveness in combination with other drugs for patients with hormone receptor-positive, HER2-negative advanced breast cancer (ABC). The trial's results recently shared details on distinct cohorts, emphasizing the drug's therapeutic potential.
Future Directions: VIKTORIA-2 and More
Building on previous successes, Celcuity is also enrolling patients in the VIKTORIA-2 trial, which aims to assess the effectiveness of gedatolisib alongside a CDK4/6 inhibitor and fulvestrant for new patients presenting similar cancer profiles. These trials underline Celcuity's dedication to advancing treatment options and improving patient outcomes.
Connect with Celcuity
As the conference approaches, the emphasis on knowledge sharing is paramount. Celcuity, headquartered in Minneapolis, continually seeks to expand its reach. Interested parties can find more information on their developments and ongoing trials through their official website, which offers updated resources and contacts for further inquiries.
Company Leadership Contacts
Beyond the event, potential investors and interested parties can reach out to key figures within Celcuity. Brian Sullivan can be contacted via email for any pressing inquiries. Additionally, Vicky Hahne is available for questions regarding investor relations.
Frequently Asked Questions
What is the focus of the Evercore Healthcare Conference?
The Evercore Healthcare Conference focuses on advancements in healthcare, particularly in innovative treatments and therapies in the biotechnology and pharmaceutical sectors.
Who is speaking at the conference from Celcuity?
Brian Sullivan, the CEO and Co-founder of Celcuity, is scheduled to speak at the event.
How can I access the live webcast of the event?
The live webcast can be accessed through a link shared by Celcuity, ensuring that a global audience can tune in to the discussions.
What are Celcuity's main therapeutic focuses?
Celcuity primarily focuses on developing targeted therapies for treating various solid tumors, with a noted emphasis on breast cancer.
How can I find more information about Celcuity's clinical trials?
Detailed information about ongoing and upcoming clinical trials can be found on Celcuity's official website and through dedicated links to ClinicalTrials.gov.
